Give us a call
Thank you for your interest in CSL. We care about your questions and concerns. You can find the best way to contact us from the list below.
Australian Media Contact
Senior Communications Business Partner
Strategic Communications, Media & Investor Relations
Mobile: +61 0450 909 211
Email: email@example.com (non-urgent enquires)
CSL Limited Investor Relations
Phone: +61 3 9389 3470
The CSL share registry is managed and maintained by Computershare.
Phone: 1800 646 882
Outside Australia: +61 3 9415 4178
Fax: +61 3 9473 2500
Seqirus is the world’s No. 2 influenza vaccine provider in sales with operations in more than 20 countries in the US$4 billion global industry. Seqirus provides a differentiated product portfolio, possesses strong pandemic and prepandemic franchises and manages one of the world’s largest influenza vaccine manufacturing networks with operations on three continents: North America, Europe and Australia.
About CSL Behring
We are committed to saving lives and improving the quality of life for people with rare and serious diseases worldwide. This commitment is reflected in our support of therapies for people with deficient or malfunctioning blood proteins that cause diseases like bleeding disorders, primary immune deficiencies and Alpha 1 proteinase inhibitor deficiencies.